2023/09/12 更新

写真a

ナイトウ ユウシ
内藤 祐志
NAITO Yushi
所属
医学部附属病院 泌尿器科 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 学士(医学) ( 2011年3月   金沢大学 ) 

 

論文 19

  1. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer

    Naito Yushi, Kato Masashi, Kawanishi Hideji, Yamamoto Akiyuki, Sakamoto Fumitoshi, Hirabayashi Hiroki, Kobayashi Masataka, Matsukawa Yoshihisa, Kimura Tohru, Araki Hidemori, Nishikimi Toshinori, Kondo Atsuya, Yoshino Yasushi, Hashimoto Yoshimasa, Nakano Yojiro, Tsuzuki Toyonori

    PROSTATE   83 巻 ( 4 ) 頁: 307 - 315   2023年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Prostate  

    Background: In recent years, the usefulness of androgen receptor axis-targeted agents (ARATs) such as abiraterone, enzalutamide, and apalutamide for the upfront treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been demonstrated. However, it remains unclear which patients would truly benefit from these treatments. Furthermore, intraductal carcinoma of the prostate (IDC-P) is a known poor prognostic factor in patients with prostate cancer. We investigated the association between the presence of IDC-P and response to therapy in patients with mHSPC. Methods: This retrospective analysis included 318 patients with mHSPC who received treatment at Nagoya University and its 12 affiliated institutions between 2014 and 2021. Their biopsy specimens were evaluated for the presence of IDC-P. The patients were classified according to their first-line treatment into the ARAT (n = 100, receiving a combination of androgen-deprivation therapy [ADT] and ARAT) or conventional therapy (n = 218, receiving ADT with or without standard antiandrogen agents) group. We compared the overall survival (OS) and second progression-free survival (PFS2) between the ARAT and conventional groups according to the presence of IDC-P to evaluate whether presence of IDC-P predicts the response to each treatment. PFS2 was defined as the period from mHSPC diagnosis to disease progression on second-line treatment or death. Propensity score matching with one-to-one nearest-neighbor matching was used to minimize the potential effects of selection bias and confounding factors. The clinicopathological variables of the patients were well-balanced after propensity score matching. Results: Most patients in the ARAT (79%) and conventional therapy (71%) groups were ICD-P positive. In the propensity score-matched cohort, the OS and PFS2 of IDC-P-positive patients were significantly longer in the ARAT group than in the conventional group (OS: hazard ratio [HR], 0.36; p = 0.047; PFS2: HR, 0.30; p < 0.001). In contrast, no difference in OS and PFS2 was observed between the ARAT and conventional groups in IDC-P-negative patients (OS: HR, 1.09; p = 0.920; PFS2: HR, 0.40; p = 0.264). Conclusions: The findings highlight a high prevalence of IDC-P among patients with mHSPC and suggest that IDC-P positivity may be a reliable indicator that ARAT should be implemented as first-line treatment.

    DOI: 10.1002/pros.24462

    Web of Science

    Scopus

    PubMed

  2. Adiponectin can be a good predictor of urodynamic detrusor underactivity: a prospective study in men with lower urinary tract symptoms

    Ishikawa Tomohiro, Matsukawa Yoshihisa, Naito Yushi, Ishida Shohei, Majima Tsuyoshi, Gotoh Momokazu

    WORLD JOURNAL OF UROLOGY   41 巻 ( 4 ) 頁: 1117 - 1124   2023年2月

     詳細を見る

    記述言語:英語   出版者・発行元:World Journal of Urology  

    Purpose: To investigate whether circulating adiponectin, which is considered a possible marker of anti-atherogenic effects, is a useful predictor of bladder function, especially detrusor underactivity (DU), in men with lower urinary tract symptoms (LUTS). Methods: A total of 130 treatment-naïve men with non-neurogenic LUTS were prospectively stratified into two groups (the DU and non-DU groups) based on the presence or absence of DU, where DU is defined as a bladder contractility index < 100 and bladder outlet obstruction index (BOOI) < 40. The impact of serum adiponectin levels on urodynamic function, including DU, was assessed using univariate, binomial logistic regression, and receiver operating characteristic (ROC) curve analyses. Results: In total, data from 118 men were analyzed; 39 (33.0%) had DU (DU group) and 79 (67.0%) did not have DU (non-DU group). The median serum adiponectin in the DU group was significantly lower than in the non-DU group (6.2 vs 12.6 µg/mL, p < 0.001). In the binomial logistic regression analysis, lower adiponectin, smaller intravesical prostatic protrusion, and lower bladder voiding efficiency were significant factors related to DU. In the ROC analyses, serum adiponectin had the highest area under the curve value for DU diagnosis (0.849). Additionally, a cutoff value of 7.9 µg/mL for serum adiponectin level was identified for DU, which yielded a sensitivity and specificity of 79% and 90%, respectively. Conclusions: The serum adiponectin level was significantly associated with bladder function and may be a useful marker for predicting DU in men with LUTS.

    DOI: 10.1007/s00345-023-04341-y

    Web of Science

    Scopus

    PubMed

  3. Validation and clinical utility of the Nagoya diagnostic criteria for detrusor underactivity in men

    Matsukawa Y., Naito Y., Nakane W., Kamizyo S., Miyazi T., Ishida S., Gotoh M.

    EUROPEAN UROLOGY   83 巻   頁: S34 - S35   2023年2月

     詳細を見る

  4. Adiponectin predicts urodynamic detrusor underactivity: A prospective study of elderly men with lower urinary tract symptoms

    Matsukawa Y., Ishida S., Naito Y., Matsuo K., Ishikawa T., Gotoh M.

    EUROPEAN UROLOGY   83 巻   頁: S69 - S70   2023年2月

     詳細を見る

  5. Two types of detrusor underactivity in men with nonneurogenic lower urinary tract symptoms

    Matsukawa Yoshihisa, Naito Yushi, Ishida Shohei, Matsuo Kazuna, Majima Tsuyoshi, Gotoh Momokazu

    NEUROUROLOGY AND URODYNAMICS   42 巻 ( 1 ) 頁: 73 - 79   2023年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Neurourology and Urodynamics  

    Aims: To clarify the clinical features of men with nonneurogenic detrusor underactivity (DU) by focusing on storage dysfunction (SD). Methods: We retrospectively reviewed the clinical and urodynamic data of men with nonneurogenic DU. Patients were divided into two groups according to the presence or absence of SD, such as detrusor overactivity (DO) and reduced bladder compliance (BC). Patient characteristics, lower urinary tract symptoms (LUTS), and urodynamic parameters were compared. DU was defined as bladder contractility index (BCI) ≤ 100 and bladder outlet obstruction index (BOOI) ≤ 40. Results: Of 212 men with DU, 123 (58.0%) had concomitant SD (SD + DU group), and 89 (42.0%) had only DU (DU-only group). Age, prostate volume, and severity of storage symptoms were significantly higher in the SD + DU group. Particularly, >80% of men in the SD + DU group met the diagnostic criteria for overactive bladder in Japan, which was significantly higher than the 26% of men in the DU-only group. The frequency of urinary urgency incontinence (UUI) was also significantly higher in the SD + DU group (65% vs. 12% in DU-only group). In contrast, voiding symptoms, including straining, were more severe in the DU-only group. Regarding the urodynamic parameters, compared to the DU-only group, bladder capacity was significantly smaller and BOOI and BCI were significantly higher in the SD + DU group. However, there was no significant difference in the maximum flow rate and bladder voiding efficiency. Conclusions: Approximately 60% of men with DU had SD, such as DO and/or reduced BC, whereas the remaining 40% had increased bladder capacity without an increase in detrusor pressure during the storage phase. There were significant differences in the storage and voiding symptoms between the groups. It is important to divide patients with DU based on SD to accurately clarify the clinical picture of DU.

    DOI: 10.1002/nau.25044

    Web of Science

    Scopus

    PubMed

  6. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan

    Naito Yoichi, Sunami Kuniko, Kage Hidenori, Komine Keigo, Amano Toraji, Imai Mitsuho, Koyama Takafumi, Ennishi Daisuke, Kanai Masashi, Kenmotsu Hirotsugu, Maeda Takahiro, Morita Sachi, Sakai Daisuke, Watanabe Kousuke, Shirota Hidekazu, Kinoshita Ichiro, Yoshioka Masashiro, Mamesaya Nobuaki, Ito Mamoru, Kohsaka Shinji, Saigusa Yusuke, Yamamoto Kouji, Hirata Makoto, Tsuchihara Katsuya, Yoshino Takayuki

    JAMA NETWORK OPEN   5 巻 ( 12 ) 頁: e2245081   2022年12月

     詳細を見る

    記述言語:英語   出版者・発行元:JAMA network open  

    Importance: Quality assurance of molecular tumor boards (MTBs) is crucial in cancer genome medicine. Objective: To evaluate the concordance of recommendations by MTBs and centrally developed consensus treatment recommendations at all 12 leading institutions for cancer genomic medicine in Japan using 50 simulated cases. Design, Setting, and Participants: This was a prospective quality improvement study of 50 simulated cancer cases. Molecular tumor boards from 12 core hospitals independently recommended treatment for 50 cases blinded to the centrally developed consensus treatment recommendations. The study's central committee consisted of representatives from all 12 core hospitals in Japan who selected the 50 simulated cases from The Cancer Genome Atlas database, including frequently observed genomic alterations. The central committee recommended centrally developed consensus treatment. The concordance rate for genomically matched treatments between MTBs and centrally developed consensus treatment recommendations was evaluated. Data analysis was conducted from January 22 to March 3, 2021. Exposures: Simulated cases of cancer. Main Outcomes and Measures: The primary outcome was concordance, defined as the proportion of recommendations by MTBs concordant with centrally developed consensus treatment recommendations. A mixed-effects logistic regression model, adjusted for institutes as a random intercept, was applied. High evidence levels were defined as established biomarkers for which the treatment was ready for routine use in clinical practice, and low evidence levels were defined as biomarkers for genomically matched treatment that were under investigation. Results: The Clinical Practice Guidance for Next-Generation Sequencing in Cancer Diagnosis and Treatment (edition 2.1) was used for evidence-level definition. The mean concordance between MTBs and centrally developed consensus treatment recommendations was 62% (95% CI, 57%-65%). Each MTB concordance varied from 48% to 86%. The concordance rate was higher in the subset of patients with colorectal cancer (100%; 95% CI, 94.0%-100%), ROS1 fusion (100%; 95% CI, 85.5%-100%), and high evidence level A/R (A: 88%; 95% CI, 81.8%-93.0%; R:100%; 95% CI, 92.6%-100%). Conversely, the concordance rate was lower in cases of cervical cancer (11%; 95% CI, 3.1%-26.1%), TP53 mutation (16%; 95% CI, 12.5%-19.9%), and low evidence level C/D/E (C: 30%; 95% CI, 24.7%-35.9%; D: 25%; 95% CI, 5.5%-57.2%; and E: 18%; 95% CI, 13.8%-23.0%). Multivariate analysis showed that evidence level (high [A/R] vs low [C/D/E]: odds ratio, 4.4; 95% CI, 1.8-10.8) and TP53 alteration (yes vs no: odds ratio, 0.06; 95% CI, 0.03-0.10) were significantly associated with concordance. Conclusions and Relevance: The findings of this study suggest that genomically matched treatment recommendations differ among MTBs, particularly in genomic alterations with low evidence levels wherein treatment is being investigated. Sharing information on matched therapy for low evidence levels may be needed to improve the quality of MTBs.

    DOI: 10.1001/jamanetworkopen.2022.45081

    Web of Science

    Scopus

    PubMed

  7. Urodynamic risk factors of asymptomatic bacteriuria in men with non-neurogenic lower urinary tract symptoms

    Ishida Shohei, Matsukawa Yoshihisa, Yuba Takuma, Naito Yushi, Matsuo Kazuna, Majima Tsuyoshi, Gotoh Momokazu

    WORLD JOURNAL OF UROLOGY   40 巻 ( 12 ) 頁: 3035 - 3041   2022年12月

     詳細を見る

    記述言語:英語   出版者・発行元:World Journal of Urology  

    Purpose: To investigate the prevalence of asymptomatic bacteriuria (ASB) in middle-aged and older men with non-neurogenic lower urinary tract symptoms (LUTS) and clarify urodynamic factors related to the presence of ASB. Methods: We retrospectively reviewed the clinical data of men with LUTS who underwent urine culture examination, LUTS severity assessment, and urodynamic studies. The patients were allocated into two groups (the ASB + LUTS and LUTS-only) according to presence or absence of ASB. The patients’ characteristics and urodynamic factors related to the development of ASB were assessed using univariate, binomial logistic regression, and receiver-operating characteristic (ROC) curve analyses. Results: Of 440 men, 93 (21.1%) had ASB. Parameters related to voiding functions, such as maximum flow rate, post-void residual urine volume, bladder voiding efficiency (BVE), and bladder contractility index (BCI), were significantly reduced in the ASB + LUTS group, while bladder outlet obstruction index was not different between the groups. Binomial logistic regression analysis showed that the presence of diabetes, lower BCI, and lower BVE were significantly associated with the presence of ASB. In addition, ROC analysis identified 55% as the optimal cutoff value of BVE for the presence of ASB, with a sensitivity of 84% and specificity of 83%. Conclusions: ASB was found in > 20% of men with non-neurogenic LUTS and was associated with decreased bladder contractility and decreased BVE. BVE could predict presence of ASB with high sensitivity and specificity.

    DOI: 10.1007/s00345-022-04194-x

    Web of Science

    Scopus

    PubMed

  8. Clinical features and urodynamic findings in elderly men with chronic prostatitis

    Matsukawa Yoshihisa, Funahashi Yasuhito, Ishida Shohei, Naito Yushi, Yuba Takuma, Matsuo Kazuna, Gotoh Momokazu

    INTERNATIONAL JOURNAL OF UROLOGY   29 巻 ( 5 ) 頁: 441 - 445   2022年5月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Urology  

    Objectives: To investigate the complication rate of chronic prostatitis/chronic pelvic pain syndrome in men with lower urinary tract symptoms, and to clarify their clinical features and urodynamic findings. Methods: We retrospectively reviewed the clinical data of treatment-naïve men with lower urinary tract symptoms. Patients were divided into two groups (chronic prostatitis/chronic pelvic pain syndrome + lower urinary tract symptoms and lower urinary tract symptoms only) according to the presence or absence of chronic prostatitis/chronic pelvic pain syndrome, and the patient characteristics as well as the parameters of lower urinary tract symptoms and lower urinary tract function assessed by urodynamics were compared. The diagnostic criteria for chronic prostatitis/chronic pelvic pain syndrome included a complaint of pelvic pain for ≥3 months, National Institutes of Health Chronic Prostatitis Symptom Index pain subscore ≥4, and negative culture of a urine specimen collected after prostate massage. Results: Out of 386 men, 123 (31.9%) had chronic prostatitis/chronic pelvic pain syndrome. Parameters of lower urinary tract symptoms and National Institutes of Health Chronic Prostatitis Symptom Index scores were significantly higher in the chronic prostatitis/chronic pelvic pain syndrome + lower urinary tract symptoms group. Although there were no significant intergroup differences in voiding parameters such as maximum flow rate and bladder outlet obstruction index, storage functions such as the incidence of detrusor overactivity and bladder compliance were significantly reduced in the chronic prostatitis/chronic pelvic pain syndrome + lower urinary tract symptoms group. The multivariable regression analysis revealed that a low serum total testosterone level (<3.5 ng/mL), complications of hyperlipidemia, and presence of overactive bladder and detrusor overactivity were significantly associated with the development of chronic prostatitis/chronic pelvic pain syndrome. Conclusions: Chronic prostatitis causes a significant decrease in storage function, such as an increase in detrusor overactivity. Additionally, low serum testosterone levels and hyperlipidemia were found to be significantly associated with the development of chronic prostatitis/chronic pelvic pain syndrome in men with lower urinary tract symptoms.

    DOI: 10.1111/iju.14805

    Web of Science

    Scopus

    PubMed

  9. Clinical features and urodynamic findings in elderly males with chronic prostatitis

    Matsukawa Y., Funahashi Y., Ishida S., Naito Y., Matsuo K., Gotoh M.

    EUROPEAN UROLOGY   81 巻   頁: S648 - S648   2022年2月

     詳細を見る

  10. Grade group 2 (10% >= GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate

    Kato Masashi, Hirakawa Akihiro, Sato Hiroyuki, Hanazawa Ryoichi, Naito Yushi, Tochigi Kosuke, Sano Tomoyasu, Ishida Shohei, Funahashi Yasuhito, Fujita Takashi, Matsukawa Yoshihisa, Hattori Ryohei, Tsuzuki Toyonori

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   26 巻 ( 4 ) 頁: 764 - 769   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:International Journal of Clinical Oncology  

    Background: It has been argued that grade group 2 (GG2) with a low Gleason pattern 4 (GP4) proportion should be an indication for active surveillance (AS) of prostate cancer (PCa). However, the cut-off GP4 proportion for AS remains unclear. Here, we evaluated the effect of GP4 proportion and IDC-P on cancer recurrence following radical prostatectomy (RP) in GG1 and GG2 patients, and identified candidates for AS. Methods: We retrospectively evaluated 646 patients with PCa who underwent RP between 2005 and 2014, and whose specimens were of GG1 or GG2 status. Results: The GGs were as follows: GG1, 25.2% (n = 163); GG2 (5% ≥ GP4), 11.4% (n = 74); GG2 (5% < GP4 ≤ 10%), 25.9% (n = 167); and GG2 (20% ≤ GP4), 37.5% (n = 242). IDC-P was detected in 26 patients (4%), i.e., in 2/167 GG2 (5% < GP4 ≤ 10%; 1%) cases and 24/242 GG2 (20% ≤ GP4; 10%) cases. GG2 patients with IDC-P exhibited a significantly poorer prognosis than did those without IDC-P (P < 0.0001), as did GG2 (20% ≤ GP4) patients without IDC-P (P < 0.05). The GG2 (5% ≥ GP4) and (5% < GP4 ≤ 10%) groups exhibited prognoses similar to those of the GG1 patients. In multivariate analysis, GG2 (20% ≤ GP4) without IDC-P, the presence of IDC-P, and the prostate-specific antigen level at diagnosis significantly predicted prognosis (P < 0.05, < 0.0001, and < 0.0001, respectively). Conclusion: Our findings suggest that GG2 (GP4 ≤ 10%) patients could be indicated for AS, similar to GG1 patients, given the risk of IDC-P tumors.

    DOI: 10.1007/s10147-020-01841-4

    Web of Science

    Scopus

    PubMed

  11. Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer

    Kato Masashi, Hirakawa Akihiro, Kobayashi Yumiko, Yamamoto Akiyuki, Naito Yushi, Tochigi Kosuke, Sano Tomoyasu, Ishida Shohei, Funahashi Yasuhito, Fujita Takashi, Matsukawa Yoshihisa, Hattori Ryohei, Tsuzuki Toyonori

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   25 巻 ( 12 ) 頁: 2130 - 2137   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:International Journal of Clinical Oncology  

    Background: The number of core needle biopsies in metastatic prostate cancer cases are sometimes reduced to avoid various complications. We analyzed whether core needle biopsy number influence IDC-P detection rate in patients with metastatic castration-sensitive prostate cancer (mHSPC). Methods: We retrospectively evaluated data from 150 patients diagnosed with mHSPC. Subjects were allocated to three groups according to the number of core biopsies performed: ≤ 5, 6–9, and ≥ 10. The study endpoints were the cancer-specific survival (CSS) and overall survival (OS) rates. Results: For patients who underwent ≥ 10 core biopsies, a significant difference on CSS was detected between with or without IDC-P (P = 0.016). On the other hand, the difference decreased as the number of core biopsies became smaller (6–9; P = 0.322 and ≤ 5; P = 0.815). A similar trend was identified for the OS outcome. A significant difference on OS was also found between with or without IDC-P in patients who underwent ≥ 10 and 6–9 core needle biopsies (P = 0.0002 and 0.017, respectively), but not in those who underwent ≤ 5 core biopsies (P = 0.341). IDC-P served as a stronger prognostic marker for CSS and OS than did the other factors included in the multivariate analysis for patients had ≥ 10 core biopsies (P = 0.016, and P = 0.0014, respectively). Conclusions: Given the IDC-P detection and its value as a prognostic marker, we propose the performance of ≥ 10 core biopsy procedures in patients diagnosed with mHSPC to minimize the sampling error of the IDC-P.

    DOI: 10.1007/s10147-020-01756-0

    Web of Science

    Scopus

    PubMed

  12. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study

    Naito Yushi, Kato Masashi, Kawanishi Hideji, Yuguchi Yuri, Yuba Takuma, Ishikawa Tomohiro, Hattori Kyosuke, Yamamoto Akiyuki, Sano Tomoyasu, Matsukawa Yoshihisa, Kimura Toru, Nishikimi Toshinori, Hattori Ryohei, Tsuzuki Toyonori, Gotoh Momokazu

    PROSTATE   80 巻 ( 15 ) 頁: 1373 - 1380   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:Prostate  

    Background: The optimal sequential therapy for castration-resistant prostate cancer (CRPC) remains unknown. In recent years, some doubts have emerged regarding the clinical benefit of sequential therapy with androgen receptor axis-targeted agents (ART) such as abiraterone (ABI) or enzalutamide (ENZ) for patients with CRPC. We compared the effect of ART-to-ART (AA) sequential therapy after castration resistance with that of docetaxel (DTX)-combined sequential therapy (ART to DTX or DTX to ART) in patients with CRPC. Methods: We retrospectively identified and analyzed the data of 315 patients with CRPC treated in our seven affiliated institutions between 2009 and 2019. All patients received either DTX or ART (ABI or ENZ) as the first- or second-line therapy after castration resistance. We compared the overall survival (OS) and the second progression-free survival (PFS2), calculated from the initiation of first-line therapy after castration resistance, between the AA sequence group and the DTX-combined sequence group. PFS2 was defined as the period from the start of first-line treatment after castration resistance to progression on second-line treatment. To minimize selection bias from possible confounders, we performed propensity score matching using one-to-one nearest neighbor matching without replacement. Results: Overall, 106 and 209 patients were administered the AA sequential therapy and DTX-combined sequential therapy, respectively. The clinicopathological variables of patients were well balanced after propensity score matching, and there were no significant differences between the two groups. In the propensity score-matched cohort, OS was not significantly different between the two groups (median, 37.9 vs. 45.4 months; hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.68–1.79; p =.701), while PFS2 was significantly shorter in the AA group than in the DTX-combined group (median, 12.9 vs. 21.6 months; HR, 1.70; 95% CI, 1.16–2.48; p =.007). Conclusions: Certain patients with CRPC can benefit from ART-to-ART sequential therapy in a daily clinical setting.

    DOI: 10.1002/pros.24069

    Web of Science

    Scopus

    PubMed

  13. Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study

    Matsukawa Yoshihisa, Naito Yushi, Funahashi Yasuhito, Ishida Shohei, Fujita Takashi, Tochigi Kosuke, Kato Masashi, Gotoh Momokazu

    NEUROUROLOGY AND URODYNAMICS   39 巻 ( 7 ) 頁: 1994 - 2002   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:Neurourology and Urodynamics  

    Aims: To compare the efficacy of cernitin pollen extract (cernitin) or tadalafil for treating persistent chronic pelvic pain despite α1-blocker monotherapy in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and lower urinary tract symptoms (LUTS). Methods: A total of 100 patients with refractory CP/CPPS despite ongoing α1-blocker monotherapy were randomized to receive add-on therapy with either cernitin (4 capsules/day) or tadalafil (5 mg/d) for 12 weeks. At week 12, changes from baseline in the patients’ CP/CPPS, LUTS, and voiding function, as assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and uroflowmetry, respectively, were compared between the groups. Results: The final analysis included 42 and 45 patients in the cernitin and tadalafil groups, respectively. Although the NIH-CPSI total, NIH-CPSI pain sub-score, and NIH-CPSI quality of life sub-score significantly improved in both groups, the cernitin (vs tadalafil) group showed significantly greater improvements in the NIH-CPSI total score (−6.8 vs −4.6; P =.02) and NIH-CPSI pain sub-score (−4.1 vs −1.5; P <.001). Half (50%) of the patients in the cernitin group showed a reduction greater than 50% in their NIH-CPSI pain sub-score; in the tadalafil group, only four patients (8.9%) showed ≥50% improvement (P <.001). In contrast, the improvement in LUTS was significantly superior in the tadalafil group. Conclusion: Both cernitin and tadalafil significantly ameliorated chronic pelvic pain in patients with refractory CP/CPPS. The add-on of cernitin was more effective than tadalafil for pelvic pain and discomfort.

    DOI: 10.1002/nau.24454

    Web of Science

    Scopus

    PubMed

  14. DAILY AMOUNT OF URINARY INCONTINENCE IMMEDIATELY AFTER CATHETER REMOVAL CAN BE A GOOD PREDICTOR OF LONG-TERM URINARY INCONTINENCE FOLLOWING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY

    Matsukawa Y., Funahashi Y., Naito Y., Tochigi K., Hibino T., Kato M., Gotoh M.

    NEUROUROLOGY AND URODYNAMICS   39 巻   頁: S100 - S101   2020年7月

     詳細を見る

    記述言語:日本語  

    Web of Science

  15. Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate

    Yamamoto Akiyuki, Kato Masashi, Hattori Kyosuke, Naito Yushi, Tochigi Kosuke, Sano Tomoyasu, Kawanishi Hideji, Ishikawa Tomohiro, Yuba Takuma, Hattori Ryohei, Gotoh Momokazu, Tsuzuki Toyonori

    BJU INTERNATIONAL   125 巻 ( 5 ) 頁: 702 - 708   2020年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:BJU International  

    Objective: To evaluate the efficacy of docetaxel and androgen receptor axis-targeted (ARAT) agents in patients with castration-resistant prostate cancer (CRPC) with intraductal carcinoma of the prostate (IDC-P) using a propensity score-matched analysis. Patients and Methods: We retrospectively identified 309 patients with CRPC from February 2007 to February 2016 at Nagoya University and its affiliated hospitals. All patients received initial androgen-deprivation therapy (ADT). After progression to CRPC, they received docetaxel or ARAT (abiraterone or enzalutamide) as first-line life-prolonging therapy. Docetaxel (70–75 mg/m2) every 3 weeks vs enzalutamide (160 mg) once daily orally or abiraterone (1 g) once daily plus prednisone (5 mg) twice daily orally was administered. The primary outcome of interest was overall survival (OS) from the time of CRPC diagnosis. A propensity score analysis with a 1:1 ratio using an optimal matching algorithm was used to adjust for confounding factors. Results: Overall, 234 patients were analysed. Propensity score-matching identified 85 patients in each group. There were no significant differences in patient characteristics between the groups. The median OS in the docetaxel group was 38.2 vs 58.3 months in the ARAT group (P = 0.03). For patients with IDC-P, OS was significantly longer in the ARAT group than the docetaxel group (P = 0.01), and there was no significant difference in each group, as in patients without IDC-P (P = 0.67). A multivariate analysis showed that the presence of IDC-P, duration of primary ADT, visceral metastasis, and administration of ARAT as the first-line treatment for CRPC were independent prognostic factors for OS. Conclusion: Administration of ARAT as the first-line treatment for CRPC may prolong OS more than that of docetaxel, especially in patients with IDC-P.

    DOI: 10.1111/bju.14970

    Web of Science

    Scopus

    PubMed

  16. Efficacy of sequential therapy comprising of docetaxel, abiraterone, enzalutamide, and cabazitaxel in patients with castration-resistant prostate cancer

    Yamamoto Akiyuki, Kato Masashi, Tsuzuki Toyonori, Gotoh Momokazu, Naito Yushi, Hattori Kyosuke, Tochigi Kosuke, Yuba Takuma, Kawanishi Hideji

    JOURNAL OF CLINICAL ONCOLOGY   38 巻 ( 6 )   2020年2月

     詳細を見る

    記述言語:日本語  

    Web of Science

  17. [ADOPTION OF ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR THE MANAGEMENT OF PATIENTS UNDERGOING RADICAL CYSTECTOMY IN JAPAN].

    Naito Y, Kanazawa H, Okada Y, Nagayama J, Syo N, Yamamoto A, Kojima I, Terashima Y, Nagai T

    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology   111 巻 ( 1 ) 頁: 9 - 15   2020年

     詳細を見る

    記述言語:日本語  

    DOI: 10.5980/jpnjurol.111.9

    PubMed

  18. Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy.

    Kojima I, Naito Y, Yamamoto A, Terashima Y, Sho N, Nagayama J, Okada Y, Nagai T

    Osteoporosis and sarcopenia   5 巻 ( 4 ) 頁: 128 - 131   2019年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.afos.2019.11.001

    PubMed

  19. [A CASE OF RETROPERITONEAL HEMORRHAGE CAUSED BY THE INSERTION OF A URETERAL ACCESS SHEATH. A RARE COMPLICATION ASSOCIATED WITH FLEXIBLE TRANSURETHRAL LITHOTRIPSY (fTUL)].

    Kojima I, Okada Y, Kono Y, Naito Y, Terashima Y, Nagai T

    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology   109 巻 ( 1 ) 頁: 50 - 53   2018年

     詳細を見る

    記述言語:日本語  

    DOI: 10.5980/jpnjurol.109.50

    PubMed

▼全件表示

MISC 1

  1. A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors.

    Nakane W, Naito Y, Morishita K, Matsuo K, Ishida S, Matsukawa Y  

    Nagoya journal of medical science84 巻 ( 4 ) 頁: 865 - 870   2022年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transurethral resection of the bladder tumor revealed pT2 or higher urothelial carcinoma. The patient underwent total cystectomy with an ileal conduit diversion. Histological examination revealed a primary undifferentiated bladder carcinoma with a sarcoma component, pT3aN0M0. Postoperative adjuvant chemotherapy with gemcitabine plus carboplatin was administered. However, this regimen was discontinued after one course due to significant myelosuppression. Four months after total cystectomy, a pelvic tumor with suspected local recurrence was detected on CT. The patient was diagnosed with recurrent undifferentiated carcinoma with a sarcoma component by a transperineal ultrasound-guided biopsy. Local radiation therapy and immunotherapy with immune checkpoint inhibitors were prescribed. After three courses of immunotherapy with pembrolizumab, the primary tumor disappeared. Upon continuing immune checkpoint inhibitor treatment, the patient has maintained a complete response without tumor recurrence in the following six months.

    DOI: 10.18999/nagjms.84.4.865

    Scopus

    PubMed

講演・口頭発表等 5

  1. 去勢抵抗性前立腺癌に対する三次治療までの薬剤選択の検討

    内藤 祐志

    第109回日本泌尿器科学会総会  2021年12月7日 

     詳細を見る

    開催年月日: 2021年12月

    記述言語:日本語   会議種別:口頭発表(一般)  

  2. 複雑化する前立腺がん薬物治療のLandscape 招待有り

    内藤 祐志

    Young urologist seminar  2021年12月3日 

     詳細を見る

    開催年月日: 2021年12月

    記述言語:日本語   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  3. OABの薬物治療に対する難治性の判断とその予測因子 招待有り

    内藤 祐志

    第71回日本泌尿器科学会中部総会  2021年10月9日 

     詳細を見る

    開催年月日: 2021年10月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

  4. ロボット支援手術経験初期のPitfallとTips 招待有り

    内藤 祐志

    Next generation urologist seminar  2021年3月12日 

     詳細を見る

    開催年月日: 2021年3月

    記述言語:日本語   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  5. 去勢抵抗性前立腺癌に対するARAT逐次療法の有用性 招待有り

    内藤 祐志

    Nagoya Urology Seminar  2021年1月29日 

     詳細を見る

    開催年月日: 2021年1月

    記述言語:日本語   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    開催地:名古屋